Merck & Co., Inc. (NYSE:MRK) Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 9.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 458,601 shares of the company’s stock after selling 46,089 shares during the quarter. Gabelli Funds LLC’s holdings in Merck & Co., Inc. were worth $35,147,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in MRK. Financial Avengers Inc. increased its position in shares of Merck & Co., Inc. by 115.8% during the fourth quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock worth $25,000 after purchasing an additional 176 shares in the last quarter. Moisand Fitzgerald Tamayo LLC increased its position in shares of Merck & Co., Inc. by 78.0% during the fourth quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock worth $27,000 after purchasing an additional 156 shares in the last quarter. Bellwether Advisors LLC increased its position in shares of Merck & Co., Inc. by 460.0% during the third quarter. Bellwether Advisors LLC now owns 420 shares of the company’s stock worth $31,000 after purchasing an additional 345 shares in the last quarter. Ritter Daniher Financial Advisory LLC increased its position in shares of Merck & Co., Inc. by 33.9% during the fourth quarter. Ritter Daniher Financial Advisory LLC now owns 517 shares of the company’s stock worth $40,000 after purchasing an additional 131 shares in the last quarter. Finally, Steward Financial Group LLC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth approximately $40,000. 72.88% of the stock is owned by institutional investors and hedge funds.

Shares of Merck & Co., Inc. stock traded up $1.46 during trading hours on Friday, hitting $93.55. The company’s stock had a trading volume of 11,757,111 shares, compared to its average volume of 12,446,518. The firm has a fifty day moving average of $85.45 and a 200-day moving average of $80.91. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $94.56. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.02 and a current ratio of 1.40. The stock has a market cap of $236.57 billion, a price-to-earnings ratio of 16.74, a P/E/G ratio of 1.24 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its earnings results on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.31. Merck & Co., Inc. had a return on equity of 47.86% and a net margin of 26.27%. The firm had revenue of $15.90 billion for the quarter, compared to analyst estimates of $14.64 billion. During the same quarter in the prior year, the company earned $1.40 EPS. Merck & Co., Inc.’s revenue was up 31.6% on a year-over-year basis. On average, sell-side analysts expect that Merck & Co., Inc. will post 7.31 earnings per share for the current fiscal year.

Several analysts recently commented on MRK shares. JPMorgan Chase & Co. dropped their price target on Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating for the company in a research report on Friday, January 28th. StockNews.com assumed coverage on Merck & Co., Inc. in a report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Morgan Stanley dropped their target price on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. Barclays upped their target price on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a report on Tuesday, April 12th. Finally, SVB Leerink dropped their target price on Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating for the company in a report on Thursday, April 21st. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $90.69.

About Merck & Co., Inc. (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.